Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476734 · ClinicalTrials.gov registry record
FDG-PET/CT Imaging as Early Predictor of DP
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 9
- Enrollment target
NCT02476734: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02476734 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02476734 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
In this study the investigators would like to describe FDG-PET/CT responses in patients who are receiving CART-19 immunotherapy for Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) as part of UPCC #13413. Subjects will undergo two FDG-PET/CTs. One performed within 6 weeks of CART-19 infusion and a repeat scan at about 1 month after infusion.
Primary Outcome
global objective tumor response measured from serial PET/CT scans as the change (absolute and relative (%)) in total metabolically active tumor volume (i.e., the total volume (in cc) of FDG-avid tumor throughout the body) between pre-treatment and post-treatment PET/CT scans.
Interventions
- OTHER There is no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-08 |
What the finished NCT02476734 record still lists
NCT02476734 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which There is no intervention is the first listed.
NCT02476734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02476734 about?
NCT02476734 is a clinical study titled "FDG-PET/CT Imaging as Early Predictor of DP". In this study the investigators would like to describe FDG-PET/CT responses in patients who are receiving CART-19 immunotherapy for Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) as part of UPCC #13413. Subjects will undergo two FDG-PET/CTs. One perfo...
What is the current status of trial NCT02476734?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2014-08. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02476734?
The interventions under investigation include: There is no intervention (OTHER).
Who is sponsoring clinical trial NCT02476734?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia